NCT01324752

A Drug-Drug Interaction Study of Losartan and PA21

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Vifor Pharma · Industry
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if Losartan potassium is affected by PA21.

Conditions

• Drug Interaction Potentiation

Interventions

Type	Name	Description
DRUG	PA21 and Losartan with Food	The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
DRUG	No PA21; Losartan with food	The maximum dose of Losartan will be 100 mg/day.
DRUG	PA21 with food and Losartan 2 hours later	The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.

Timeline

• Start date: 2011-03-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2011-03-29
• Last updated: 2012-12-21

Locations

1 site across 1 country: United States